



Official Title: A phase II exploratory study of durvalumab (MEDI4736) in HIV-1 patients with advanced solid tumors.

NCT Number: NCT03094286

Document Dates: Protocol Amendment Version 4.1: 14 November 2018

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04_ [REDACTED]

Version Number 4.1

Date 14th November 2018



**A PHASE II EXPLORATORY STUDY OF DURVALUMAB
(MEDI4736) IN HIV-1 PATIENTS WITH ADVANCED SOLID
TUMORS**

DURVAST: Durvalumab in solid tumors

Study Sponsor: Fundación GECP

EudraCT Number: 2016-004524-38

Sponsor code: GECP 16/04

[REDACTED]

Version 4.1

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04_ [REDACTED]

Version Number 4.1

Date 14th November 2018

Protocol Signature Page

A PHASE II EXPLORATORY STUDY OF DURVALUMAB (MEDI4736) IN HIV-1 PATIENTS WITH ADVANCED SOLID TUMORS

DURVAST: Durvalumab in solid tumors

Sponsor code: GECP 16/04

Approved By

Signature



Principal investigator

Signature



Study coordinator

Signature



Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04_ [REDACTED]

Version Number 4.1

Date 14th November 2018

Fundación GECP President

Principal Investigator Protocol Signature Page

Study Title: “A phase II exploratory study of durvalumab (MEDI4736) in HIV-1 patients with advanced solid tumors”

Sponsor protocol code: GECP 16/04

EudraCT Number: 2016-004524-38

Protocol version: v 4.1, 14th November 2018

As principal investigator of this site, I hereby confirm that:

I have read the protocol and agree that it contains all necessary details for conducting this trial. I will conduct the trial as outlined in the following protocol and in compliance with GCP, and will apply due diligence to avoid protocol deviations.

I will provide copies of the protocol and all drug information relating to pre-clinical and prior clinical experience furnished to me by the Fundación GECP, to all physicians responsible to me who participate in this trial. I will discuss this material with them to assure that they are fully informed regarding the drug and the conduct of the trial.

I agree to keep accurate records on all patient information including patient's informed consent statement, drug shipment and return forms, and all other information collected during the trial for a minimum period of 25 years according to the new Royal Decree 1090/2015 approved in Spain.

Name of Principal Investigator: _____

Institution's name and place: _____

Signature

Date

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04_ [REDACTED]

Version Number 4.1

Date 14th November 2018

Investigational Drug Substance(s)	Durvalumab (Medi4736)
Version	4.1
Date	14 th November 2018

A phase II exploratory study of durvalumab (MEDI4736) in HIV-1 patients with advanced solid tumors

Sponsor: Fundación GECP
Av. Meridiana, 358 6^a Planta
08027 Barcelona
Phone: +34 93 430 20 06 / Fax: +34 93 419 17 68
E-mail: gecp@gecp.org

Principal Investigator: [REDACTED]
Instituto Oncológico Dr. Rosell
Oncology Department
Sabino Arana 5
08028 Barcelona
[REDACTED]
[REDACTED]

Study Coordinator: [REDACTED]
Instituto Oncológico Dr. Rosell
Oncology Department
Sabino Arana 5
08028 Barcelona
[REDACTED]
[REDACTED]

PROTOCOL SYNOPSIS

Clinical Protocol GECP16/04 (ESR 15-10869)

<p>Study Title:Phase II exploratory study of durvalumab (MEDI4736) in HIV-1 patients with advanced solid tumors</p>
<p>Protocol Number: GECP 16/04 [REDACTED]</p>
<p>Clinical Phase: II</p>
<p>Study Duration: Recruitment period will be 12 months First subject in: Q1, 2016 Last subject out: Q1, 2018 Survival follow-up will continue until 5 years after the last subject receives the last dose of durvalumab</p>
<p>Investigational Product(s) and Reference Therapy: Durvalumab will be supplied in glass vials containing 500 mg of liquid solution at a concentration of 50 mg/mL for intravenous (IV) administration.</p>
<p>Research Hypothesis PD-1/ PD-L1 coinhibitory pathway plays a significant role in the regulation of the immune response in both chronic infectious diseases and cancer. Preclinical and animal data support the safety and promising activity of anti-PD-1 antibody in HIV-1 infection. Demonstrated anticancer activity and safety profile of durvalumab (MEDI4736) in cancer clinical trials. Unlikely drug interactions of durvalumab (MEDI4736) and antiretroviral treatments. We propose a phase II clinical study designed to assess the feasibility of durvalumab (MEDI4736) in HIV-1-infected individuals with solid tumors. Additionally we hope to obtain data that let us understand</p>

the possible benefit of this treatment in cancer patients and HIV infection, exploring if activity of durvalumab (MEDI4736) could be higher in cancer that has been produced at least in part due to the chronic immunosuppression. Simultaneously, it will allow us to investigate the effect of disrupting this immunoregulatory pathway might have in reversing cancer pathways and HIV-specific T-cell function during persistent chronic HIV infection in humans.

In this regard, our hypothesis is:

HIV patients with cancer have a similar outcome in terms of tolerability when treated with durvalumab (MEDI4736) monotherapy at the recommended dose than non HIV infected patients.

Objectives:

Primary Objectives:

To explore the feasibility of durvalumab (MEDI4736) monotherapy at the recommended dose of 1500mg every 4 weeks in solid tumors in HIV-1-infected patients.

Secondary Objective(s):

- To assess ORR (RECIST 1.1 and irRECIST) and duration of response.
- To evaluate the PFS rate at 6 months.
- To evaluate the OS rate at 12 months.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

Study Design:

This is a multicenter, national, nonrandomized, open label trial, phase II trial in subjects with advanced solid tumors and HIV-1 infection. Twenty patients will receive durvalumab.

Patients have to be diagnosed of advanced (metastatic or locally advanced disease without cure options with surgery or radiotherapy) cancer of any of these types: lung cancer, head and neck cancer, cervical cancer, melanoma, anal cancer, pancreatic cancer, gastro-esophageal cancer, triple negative breast cancer, bladder cancer, renal cancer, Cholangiocarcinoma, Kaposi sarcoma, lymphomas, ovarian cancer, Merkel cell carcinoma or any other tumor type in which anti PD-1 or anti PD-L1 antibodies have demonstrated antitumoral activity.

Adverse events (AEs) will be assessed throughout and evaluated using National Cancer Institute (NCI) Common Technology Criteria version of Adverse Events version 4.03 (CTCAE v 4.03).

Tumor measurements by PET-CT, CT scan or MRI will be performed every 8 weeks to determine response to treatment. Response will be evaluated using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) and immune related response criteria (irRECIST).

Treatment will continue until disease progression, significant clinical deterioration, unacceptable toxicity, any criterion for withdrawal from the trial or trial drug is fulfilled. Treatment may continue past the initial determination of disease progression per RECIST1.1 if the subject's performance status has remained stable, and if the opinion of the Investigator, the subject will benefit from continued treatment and if other criteria are fulfilled as outline in the protocol.

Number of Centers: between 5 and 10

Number of Subjects: 20

Study Population:

The study will be performed in 20 HIV patients with a histological confirmed diagnosed of advanced solid tumors (lung cancer, head and neck cancer, cervical cancer, melanoma, anal cancer, pancreatic cancer, gastro-esophageal cancer, triple negative breast cancer, bladder cancer, renal cancer, Cholangiocarcinoma, Kaposi sarcoma, lymphomas, ovarian cancer, Merkel cell carcinoma or any other tumor type in which anti PD-1 or anti PD-L1 antibodies have demonstrated antitumoral activity) for which no additional oncologic standard treatment is available, or for which the subject declines standard treatment.

Recruitment period will be 12 months.

Patients will continue their antiretroviral treatment during study time, following standard HIV-1 treatment recommendations.

Inclusion Criteria:

1. Written informed consent obtained from the subject prior to performing any protocol-related procedures, including screening evaluations.
2. Age \geq 18 years at time of study entry.
3. Eastern Cooperative Oncology Group (ECOG) 0-2
4. Life expectancy of \geq 16 weeks

5. Adequate normal organ and marrow function as defined below:

- Haemoglobin ≥ 9.0 g/dL
- Absolute neutrophil count (ANC) $\geq 1.5 \times 10^9/L$ (≥ 1500 per mm³)
- Platelet count $\geq 100 \times 10^9/L$ ($\geq 100,000$ per mm³)
- Serum bilirubin $\leq 1.5 \times$ institutional upper limit of normal (ULN). This will not apply to subjects with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of haemolysis or hepatic pathology), who will be allowed only in consultation with their physician.
- AST (SGOT)/ALT (SGPT) $\leq 2.5 \times$ institutional upper limit of normal unless liver metastases are present, in which case it must be ≤ 5 x ULN
- Serum creatinine CL > 40 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance:

Males:

$$\text{Creatinine} = \frac{\text{Weight(kg)} \times (140 - \text{Age})}{72 \times \text{serum creatinine (mg/dL)}}$$

Females:

$$\text{Creatinine} = \frac{\text{Weight (kg)} \times (140 - \text{Age}) \times 0.85}{72 \times \text{serum creatinine (mg/dL)}}$$

6. Female subjects must either be of non-reproductive potential (ie, post-menopausal by history: ≥ 60 years old and no menses for ≥ 1 year without an alternative medical cause; OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of bilateral oophorectomy) or must have a negative serum pregnancy test upon study entry.

7. Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.
8. Subjects with histologically or cytologically advanced/metastatic-documented lung cancer, head and neck cancer, cervical cancer, melanoma, anal cancer, pancreatic cancer, gastroesophageal cancer, triple negative breast cancer, bladder cancer, renal cancer, Cholangiocarcinoma, Kaposi sarcoma, lymphomas, ovarian cancer, Merkel cell carcinoma or any other tumor type in which anti PD-1 or anti PD-L1 antibodies have demonstrated antitumoral activity, refractory to standard treatment, intolerant of standard treatment, or for which no standard therapy exists or who refuse the standard treatment.
9. Subjects may be included irrespectively of number of previous lines of treatment for advanced disease.
10. Prior palliative radiotherapy must have been completed at least 2 weeks prior to start the study treatment (subjects may receive localized palliative radiotherapy while receiving study drug).
11. Documented HIV-1 infection
12. Undetectable viral load in the last analysis.
13. Subjects with brain metastases are eligible if they are asymptomatic, are treated or are neurological stable for at least 2 weeks without the use of steroids or on stable or decreasing dose of < 10 mg daily prednisone or equivalent.
14. Subjects must be following an antiretroviral therapy at the moment of the inclusion.

Exclusion Criteria:

1. Involvement in the planning and/or conduct of the study. Previous enrollment in the present study.
2. Participation in another clinical study with an investigational product during the last 4 weeks.

3. Other untreated coexisting HIV related malignancies.
4. Any previous treatment with a PD1, PD-L1 or PD-L2 inhibitor, including durvalumab.
5. Receipt of the last dose of anti-cancer therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies, other investigational agent) 28 days prior to the first dose of study drug.
6. Mean QT interval corrected for heart rate (QTc) ≥ 470 ms calculated from 3 electrocardiograms (ECGs) using Fridericia's Correction.
7. Current or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid.
8. Any unresolved toxicity (CTCAE grade 2) from previous anti-cancer therapy. *Subjects with irreversible toxicity that is not reasonably expected to be exacerbated by the investigational product may be included (e.g., hearing loss, peripherally neuropathy).*
9. Any prior Grade ≥ 3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE >Grade 1.
10. Active or prior documented autoimmune disease within the past 2 years NOTE: Subjects with vitiligo, Grave's disease, or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded.
11. Any syndrome that requires systemic corticosteroid/immunosuppressive medications EXCEPT for syndromes which would not be expected to recur in the absence of an external trigger (vitiligo, autoimmune thyroiditis, or type 1 diabetes mellitus are permitted to enroll)
12. Active or prior documented inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis).
13. History of primary immunodeficiency.
14. History of allogeneic organ transplant.
15. History of hypersensitivity to durvalumab or any excipient.

16. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active bleeding diatheses including any subject known to have evidence of acute or chronic hepatitis B or C, or psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent.
17. Known history of active tuberculosis.
18. Any serious or uncontrolled medical disorder or active infection non HIV, that would impair the ability of the subject to receive the treatment of protocol therapy under treating physician criteria.
19. Subjects with previous malignances (except non melanoma skin cancer, and cancer in situ of: bladder, gastric, colon, cervical/dysplasia, melanoma, breast) are excluded unless a complete remission was achieved at least 5 years prior to study entry and no additional therapy is required or anticipated to be required during the study period.
20. Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab.
21. Female subjects who are pregnant, breast-feeding, male, or female patients of reproductive potential who are not employing an effective method of birth control.
22. Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results.
23. Symptomatic or uncontrolled brain metastases requiring concurrent treatment, inclusive of but not limited to surgery, radiation and/or corticosteroids.
24. Subjects with uncontrolled seizures.
25. Patients with tumoral disease in the head and neck region, such as peritracheal or periesophageal lymph node involvement, with infiltration of structures of the digestive, aerea or vascular pathways that represent a risk of increased bleeding.
26. Patients with neuroendocrine tumors of pulmonary origin or pulmonary metastases with evidence of active bleeding.

27. Patients with digestive bleeding.

Investigational Product(s), Dose and Mode of Administration:

Durvalumab, 1500 mg Q4W durvalumab (equivalent to 20 mg/kg Q4W) if > 30 kg.

If patient is ≤ 30 kg, weight-based dosing, equivalent to 20 mg/kg Q4W, should be used (Appendix 2).

Study Assessments and Criteria for Evaluation:

Safety Assessments:

- Safety assessments will be based on adverse event reports, results of clinical laboratory tests, immune safety tests, physical examinations, vital sign measurements, ECOG performance status during the study and up to six months following the last study drug administration. It will be reported based on Common Terminology Criteria for Adverse Events (CTCAE) v4.0.

Efficacy Assessments:

- Tumor response evaluation will be classified according to RECIST 1.1 criteria and irRECIST criteria.

- Progression free survival at 6 months and overall survival at 12 months.

[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

Statistical Methods and Data Analysis:

The primary endpoint of the study is the feasibility of durvalumab monotherapy at the recommended dose of 1500 mg every 4 weeks in solid tumors in HIV-1-infected patients.

Feasibility will be defined based on the rate of patients that will complete at least 4 treatment cycles. One cycle is four weeks with infusions every four weeks. It is assumed that at least 50% of patients must be complete 4 cycles for considering feasible the treatment with durvalumab.

Kaplan Meier method will be used to estimate the survival function. Secondary measurements will be PFS rate at 6 months and OS rate at 12 months.

Sample Size Determination:

Sample size calculation for an estimated proportion of 50% with a level of confidence of 95% and a accuracy of 22%: 20 patients must be included in this study.

Table 1. SCHEDULE OF STUDY ASSESSMENTS

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04

Version Number 4.1

Date 14th November 2018

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04

Version Number 4.1

Date 14th November 2018

A 7x10 grid of black bars on a white background, representing a sparse matrix. The bars are of varying lengths and are positioned in a non-overlapping manner. The grid consists of 7 rows and 10 columns. The bars are black and have varying widths and heights. Some bars are positioned in the first few columns, while others are in the last few columns. The overall pattern is sparse, with most cells containing no bars.

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04

Version Number 4.1

Date 14th November 2018

The figure consists of a 10x10 grid of black bars on a white background. The bars are of various lengths and are positioned in a pattern that suggests a sparse matrix or a binary code. The grid is bounded by a thin black border.

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04

Version Number 4.1

Date 14th November 2018

A 9x10 grid of black bars on a white background, representing a sparse matrix. The bars are of varying lengths and are positioned in a non-uniform, scattered pattern across the grid. The lengths of the bars range from very short to relatively long, with some bars being as long as two or three grid cells. The pattern is not a simple regular grid, but rather a more organic, scattered arrangement of bars.

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04

Version Number 4.1

Date 14^h November 2018

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04_ [REDACTED]

Version Number 4.1

Date 14th November 2018

[REDACTED]								
[REDACTED]								
[REDACTED]								
[REDACTED]								
[REDACTED]								

[REDACTED]								
[REDACTED]								
[REDACTED]								

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04

Version Number 4.1

Date 14th November 2018

A 10x10 grid of black bars on a white background. The bars vary in length and position, creating a pattern of horizontal and vertical lines. The grid is bounded by a thin black border.

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04_

Version Number 4.1

Date 14^h November 2018

b

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04_ [REDACTED]

Version Number 4.1

Date 14th November 2018

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

TABLE OF CONTENTS	PAGE
SYNOPSIS.....	3
SCHEDULE OF ASSESSMENTS.....	5
TABLE OF CONTENTS	25
ABBREVIATIONS AND DEFINITION OF TERMS	32
1. INTRODUCTION.....	39
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
1.4 Rationale for conducting this study.....	51
1.5 Benefit/risk and ethical assessment.....	51
2. STUDY OBJECTIVES.....	52
2.1 Primary objective(s)	52
2.2 Secondary objective(s)	52
[REDACTED]	[REDACTED]
3. STUDY DESIGN.....	55
3.1 Overview of study design.....	55

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04_ [REDACTED]

Version Number 4.1

Date 14th November 2018

3.2	[REDACTED]	
3.3	Study Oversight for Safety Evaluation	57
4.	SUBJECT SELECTION.....	57
4.1	Inclusion criteria.....	57
4.2	Exclusion criteria	59
4.3	Withdrawal of Subjects from Study Treatment and/or Study	61
4.4	Replacement of subjects.....	63
5.	INVESTIGATIONAL PRODUCT(S).....	63
5.1	Durvalumab.....	63
5.1.1	[REDACTED]	[REDACTED]
	[REDACTED]	[REDACTED]
7.	[REDACTED]	[REDACTED]

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04_ [REDACTED]

Version Number 4.1

Date 14th November 2018

8

10.	ASSESSMENT OF SAFETY	86
10.1.1	Safety Parameters	86
10.1.1.1	Definition of adverse events	86
10.1.2	Definition of serious adverse events	87
10.1.3	[REDACTED]	

10.2	Assessment of safety parameters	92
10.2.1	Assessment of severity	92
10.2.2	Assessment of relationship.....	93
10.3	Recording of adverse events and serious adverse events.....	93
10.3.1	Study recording period and follow-up for adverse events and serious adverse events	94
10.3.2	Reporting of serious adverse events.....	95
10.3.3	Reporting of deaths	96
10.3.4	[REDACTED]	
11.	STATISTICAL METHODS AND SAMPLE SIZE DETERMINATION	99
11.1	Description of analysis sets.....	99
11.1.1	[REDACTED]	
11.2	Methods of statistical analyses.....	99
11.2.1	Safety Analyses.....	100


Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04_ [REDACTED]

Version Number 4.1

Date 14th November 2018



12.	ETHICAL AND REGULATORY REQUIREMENTS	102
12.1	Ethical conduct of the study	102
12.2	Ethics and regulatory review	102
12.3	Informed consent	102
12.4	Changes to the protocol and informed consent form	103
12.5	Audits and inspections	104
12.6	Insurance	104
12.7	Publications	105

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04_ [REDACTED]

Version Number 4.1

Date 14th November 2018

13.	STUDY MANAGEMENT.....	105
13.1	Training of study site personnel	105
13.2	Monitoring of the study.....	106
13.2.1	Source data	106
13.2.2	Study documentation.....	106
13.3	Study timetable and end of study	107
14.	DATA MANAGEMENT.....	107
14.1	Study governance and oversight	108

[REDACTED]

LIST OF TABLES

[REDACTED]

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04_ [REDACTED]

Version Number 4.1

Date 14th November 2018

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04_ [REDACTED]

Version Number 4.1

Date 14th November 2018

ABBREVIATIONS AND DEFINITION OF TERMS

The following abbreviations and special terms are used in this study Clinical Study Protocol.

Abbreviation or special term	Explanation
ADA	anti-drug antibody
ADCC	antibody-dependent cell-mediated cytotoxicity
AE	adverse event
AESI	adverse event of special interest
ALP	alkaline phosphatase
ALT	alanine aminotransferase
APC	antigen-presenting cells
AST	aspartate aminotransferase
AUC	area under the concentration-time curve
CDC	Complement dependent cytotoxicity
CI	confidence interval
CL	clearance
Cmax	peak concentration
Cmax,ss	peak concentration at steady state

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04_ [REDACTED]

Version Number 4.1

Date 14th November 2018

Abbreviation or special term	Explanation
Cmin	trough concentration
Cmin,ss	trough concentration at steady state
CNS	central nervous system
CR	complete response
CT	computed tomography
CTLA-4	cytotoxic T-lymphocyte-associated antigen-4
DC	disease control
DCR	disease control rate
DLT	dose-limiting toxicity
DNA	deoxyribonucleic acid
DoR	duration of response
ECG	electrocardiogram
ECOG	Eastern Cooperative Oncology Group
EDTA	disodium edetate dihydrate
Fc	fragment crystallizable
FFPE	formalin fixed paraffin embedded

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04_ [REDACTED]

Version Number 4.1

Date 14th November 2018

Abbreviation or special term	Explanation
FSH	follicle-stimulating hormone
FTIH	first-time-in-human
GCP	Good Clinical Practice
GMP	Good Manufacturing Practice
GLP	Good Laboratory Practice
HCl	hydrochloride
HIV	human immunodeficiency virus
ICF	informed consent form
ICH	International Conference on Harmonization
IEC	Independent Ethics Committee
IFN	interferon
IGF	insulin-like growth factor
IgG1	immunoglobulin G1
IgG2	immunoglobulin G2
IGSF	immunoglobulin superfamily
IHC	immunohistochemistry

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04_ [REDACTED]

Version Number 4.1

Date 14th November 2018

Abbreviation or special term	Explanation
IL	interleukin
irAE	immune-related adverse event
IRB	Institutional Review Board
IV	intravenous(ly)
MAb	monoclonal antibody
MDSC	Myeloid derived suppressor cells
MedDRA	Medical Dictionary for Regulatory Activities
miRNA	micro ribonucleic acid
MRI	magnetic resonance imaging
mRNA	messenger ribonucleic acid
MTD	maximum tolerated dose
NCI CTCAE	National Cancer Institute Common Terminology Criteria for Adverse Events
NK	natural killer
NOAEL	no-observed-adverse-effect level
NSCLC	non-small cell lung cancer
OR	objective response

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04_ [REDACTED]

Version Number 4.1

Date 14th November 2018

Abbreviation or special term	Explanation
ORR	objective response rate
OS	overall survival
PD	progressive disease
PD-1	programmed cell death 1
PD-L1	programmed cell death ligand 1
PD-L2	programmed cell death ligand 2
PFS	progression-free survival
PK	pharmacokinetic(s)
PR	partial response
PRO	patient-reported outcome
PVC	polyvinyl chloride
Q2W	every 2 weeks
Q3M	every 3 months
Q3W	every 3 weeks
Q4W	every 4 weeks
Q12W	every 12 weeks

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04_ [REDACTED]

Version Number 4.1

Date 14th November 2018

Abbreviation or special term	Explanation
QoL	quality of life
QTc	the time between the start of the Q wave and the end of the T wave corrected for heart rate
QTcF	QT interval on ECG corrected using the Frederica's formula
RCC	renal cell carcinoma
RECIST	Response Evaluation Criteria in Solid Tumors
RNA	ribonucleic acid
SAE	serious adverse event
SD	stable disease
SID	subject identification
sPD-L1	soluble programmed cell death ligand 1
SOCS3	suppressor of cytokine signaling 3
SUSAR	suspected unexpected serious adverse reaction
t ^{1/2}	half-life
TEAE	treatment-emergent adverse event
TIL	tumor infiltrating lymphocyte
Tmax	time to peak concentration

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04_ [REDACTED]

Version Number 4.1

Date 14th November 2018

Abbreviation or special term	Explanation
Tmax,ss	time to peak concentration at steady state
TNF- α	tumor necrosis factor alpha
TSH	thyroid stimulating hormone
ULN	upper limit of normal
USA	United States of America
WFI	water for injection
WHO	World Health Organization

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04_

Version Number 4.1

Date 14th November 2018

1. INTRODUCTION

Page 39 of 151

CONFIDENTIAL AND PROPRIETARY

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04_

Version Number 4.1

Date 14th November 2018

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04_ [REDACTED]

Version Number 4.1

Date 14th November 2018

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04_ [REDACTED]

Version Number 4.1

Date 14th November 2018

[REDACTED]

[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04_

Version Number 4.1

Date 14th November 2018

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04_

Version Number 4.1

Date 14th November 2018

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04_

Version Number 4.1

Date 14th November 2018

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04_

Version Number 4.1

Date 14th November 2018

104

For more information, contact the Office of the Vice President for Research and Economic Development at 319-335-1111 or research@uiowa.edu.

For more information, contact the Office of the Vice President for Research and Economic Development at 319-335-1111 or research@uiowa.edu.

For more information, contact the Office of the Vice President for Research and Economic Development at 319-273-2500 or research@uiowa.edu.

Digitized by srujanika@gmail.com

For more information, contact the Office of the Vice President for Research and Economic Development at 319-273-2500 or research@uiowa.edu.

For more information, contact the Office of the Vice President for Research and Economic Development at 319-273-2500 or research@uiowa.edu.

11. **What is the primary purpose of the `get` method in the `HttpURLConnection` class?**

Digitized by srujanika@gmail.com

For more information, contact the Office of the Vice President for Research and Economic Development at 515-294-6450 or research@iastate.edu.

© 2019 Pearson Education, Inc.

For more information, contact the Office of the Vice President for Research and Economic Development at 515-294-6450 or research@iastate.edu.

© 2013 Pearson Education, Inc.

For more information, contact the Office of the Vice President for Research and Economic Development at 515-294-6450 or research@iastate.edu.

Digitized by srujanika@gmail.com

Digitized by srujanika@gmail.com

For more information, contact the Office of the Vice President for Research and Economic Development at 319-335-1111 or research@uiowa.edu.

113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
559
560
561
562
563
564
565
566
567
568
569
569
570
571
572
573
574
575
576
577
578
579
579
580
581
582
583
584
585
586
587
588
589
589
590
591
592
593
594
595
596
597
598
599
599
600
601
602
603
604
605
606
607
608
609
609
610
611
612
613
614
615
616
617
618
619
619
620
621
622
623
624
625
626
627
628
629
629
630
631
632
633
634
635
636
637
638
639
639
640
641
642
643
644
645
646
647
648
649
649
650
651
652
653
654
655
656
657
658
659
659
660
661
662
663
664
665
666
667
668
669
669
670
671
672
673
674
675
676
677
678
679
679
680
681
682
683
684
685
686
687
688
689
689
690
691
692
693
694
695
696
697
698
699
699
700
701
702
703
704
705
706
707
708
709
709
710
711
712
713
714
715
716
717
718
719
719
720
721
722
723
724
725
726
727
728
729
729
730
731
732
733
734
735
736
737
738
739
739
740
741
742
743
744
745
746
747
748
749
749
750
751
752
753
754
755
756
757
758
759
759
760
761
762
763
764
765
766
767
768
769
769
770
771
772
773
774
775
776
777
778
779
779
780
781
782
783
784
785
786
787
788
789
789
790
791
792
793
794
795
796
797
798
799
799
800
801
802
803
804
805
806
807
808
809
809
810
811
812
813
814
815
816
817
818
819
819
820
821
822
823
824
825
826
827
828
829
829
830
831
832
833
834
835
836
837
838
839
839
840
841
842
843
844
845
846
847
848
849
849
850
851
852
853
854
855
856
857
858
859
859
860
861
862
863
864
865
866
867
868
869
869
870
871
872
873
874
875
876
877
878
879
879
880
881
882
883
884
885
886
887
888
889
889
890
891
892
893
894
895
896
897
898
899
899
900
901
902
903
904
905
906
907
908
909
909
910
911
912
913
914
915
916
917
918
919
919
920
921
922
923
924
925
926
927
928
929
929
930
931
932
933
934
935
936
937
938
939
939
940
941
942
943
944
945
946
947
948
949
949
950
951
952
953
954
955
956
957
958
959
959
960
961
962
963
964
965
966
967
968
969
969
970
971
972
973
974
975
976
977
978
979
979
980
981
982
983
984
985
986
987
988
989
989
990
991
992
993
994
995
996
997
998
999
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2159
2160
2161
2162
2163
2164
2165
2166

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04_

Version Number 4.1

Date 14th November 2018

A black and white image showing a grid of horizontal lines. The lines are white on a black background, forming a pattern of alternating black and white horizontal bands. There are approximately 20 lines in total, with a small black rectangular block positioned near the top left corner.

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04

Version Number 4.1

Date 14th November 2018

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04_

Version Number 4.1

Date 14th November 2018

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04_ [REDACTED]

Version Number 4.1

Date 14th November 2018

[REDACTED]

1.4 Rationale for conducting this study

HIV-1-infected patients with cancer have been systematically excluded from clinical trials of anti cancer drugs because of concerns related to drug interactions and the unknown effect of the underlying HIV infection on the safety and activity of the investigational drugs. Anti PD-L1 antibody durvalumab (MEDI4736) could be an active treatment both for cancer and for HIV infection, with non-expected drugs interactions.

1.5 Benefit/risk and ethical assessment

The benefit-risk relationship has been carefully considered in the planning of the trial. Based on the nonclinical and clinical studies available to date, the conduct of the trial is considered justifiable using the dose and dose regimen of the durvalumab as specified in this clinical trial protocol.

The trial shall be discontinued in the event of any new findings that indicate a relevant deterioration of the risk-benefit relationship that would render continuation of the trial unjustifiable.

The primary known risks of exposure to durvalumab include:

- Infusion-related reactions and
- irAEs

In addition, since durvalumab could induce antibody-dependent cell-mediated cytotoxicity (ADCC), there is a potential risk of tumor lysis syndrome.

Clinical trials with antibodies that block PD-1/PD-L1 interaction have been reported to produce objective response rates of 7% to 38% in patients with advanced or metastatic solid tumors, with response duration of 1 year or more for the majority of patients(22-30).

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04_ [REDACTED]

Version Number 4.1

Date 14th November 2018

Given the suboptimal treatment options for patients with recurrent locally advanced or metastatic solid tumors in HIV-1 infected patients, and the safety profile of durvalumab, the risk-benefit ratio of treatment with durvalumab in the targeted trial population is considered positive.

This clinical trial protocol will be conducted in compliance with the clinical trial protocol, ICH GCP and the applicable national regulatory requirements.

2. STUDY OBJECTIVES

2.1 Primary objective(s)

To explore the feasibility of durvalumab (MEDI4736) monotherapy at the recommended dose of 1500 mg every 4 weeks in solid tumors in HIV-1-infected patients.

HIV-1-infected patients with cancer have been systematically excluded from clinical trials of anti cancer drugs because of concerns related to drug interactions and the unknown effect of the underlying HIV infection on the safety and activity of the investigational drugs. Anti PD-L1 antibody durvalumab (MEDI4736) could be an active treatment both for cancer and for HIV infection, with non-expected drugs interactions. The aim of this study is to explore the feasibility of durvalumab (MEDI4736) in HIV-1-infected patients who are diagnosed with a solid tumor (lung cancer, head and neck cancer, cervical cancer, melanoma, anal cancer, pancreatic cancer, gastroesophageal cancer, triple negative breast cancer, bladder cancer, renal cancer, Cholangiocarcinoma, Kaposi sarcoma, lymphomas, ovarian cancer, Merkel cell carcinoma or any other tumor type in which anti PD-1 or anti PD-L1 antibodies have demonstrated antitumoral activity) for which no additional oncologic standard treatment is available, or for which the subject declines standard treatment.

2.2 Secondary objective(s)

- To assess ORR (RECIST 1.1 and irRECIST) and duration of response

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04_ [REDACTED]

Version Number 4.1

Date 14th November 2018

- To evaluate the PFS rate at 6 months
- To evaluate the OS rate at 12 months

Durvalumab (MEDI4736) has demonstrated activity in several cancer types in the general population. In this study, as secondary objective, we will analyze activity of the drug as activity in terms of Response rate according to RECIST1.1 criteria, and according to OS rate at 12 months and PFS at 6 months.

Several data indicate that anti PD-1/PD-L1 treatments in oncology could have activity in terms of OS with long responders, that it is not always correlated to classical endpoint of response rate or median survival.

In this trial given that patients will be included with different solid tumors, and different lines of treatment, activity of the drug is a secondary objective, in order to determine if activity looks similar to activity reported in solid tumors without HIV- infection.

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04_

Version Number 4.1

Date 14th November 2018

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04_ [REDACTED]

Version Number 4.1

Date 14th November 2018

3. STUDY DESIGN

3.1 Overview of study design

This is a multicenter, national, non-randomized, phase II study in HIV-1 infected patients with advanced solid tumors.

Twenty evaluable patients will be included in the trial. Patients will be included irrespective of number the previous line of treatments.


The clinical trial will be performed in 10 hospitals from the Spanish Lung Cancer Group in Spain with a competitive enrollment.

It is a single arm study. All patients included will received the treatment with durvalumab (MEDI4736). There is not placebo treated patients.

Patients must have stopped the previous treatments for cancer at least 30 days before starting study medication.

3.2 Study schema

Figure 1. Study flow chart



Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04_ [REDACTED]

Version Number 4.1

Date 14th November 2018

3.3 Study Oversight for Safety Evaluation

The whole trial may be discontinued prematurely in the event of any of the following situations:

- New information leading to unfavourable risk-benefit judgement of the trial drug, as inefficacy of the drug for this population, significant previously unknown adverse reactions or unfavourable safety findings.
- Sponsor's decision that continuation of the study is unjustifiable for medical or ethical reasons.

4. SUBJECT SELECTION

Only persons meeting the inclusion criteria and no exclusion criteria may be enrolled into the trial. Prior to performing any trial assessments not part of the routine medical care, the investigator will ensure that the subjects have provided written informed consent.

4.1 Inclusion criteria

For inclusion in the study subjects must fulfill all of the following criteria:

1. Written informed consent obtained from the subject prior to performing any protocol-related procedures, including screening evaluations.
2. Age \geq 18 years at time of study entry.
3. Eastern Cooperative Oncology Group (ECOG) 0-2.
4. Life expectancy of \geq 16 weeks.
5. Adequate normal organ and marrow function as defined below:
 - Haemoglobin \geq 9.0 g/dL
 - Absolute neutrophil count (ANC) \geq 1.5 x 10⁹/L (\geq 1500 per mm³)
 - Platelet count \geq 100 x 10⁹/L (\geq 100,000 per mm³)
 - Serum bilirubin \leq 1.5 x institutional upper limit of normal (ULN). This will not apply to subjects with confirmed Gilbert's syndrome (persistent or recurrent

hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only in consultation with their physician.

- AST (SGOT)/ALT (SGPT) \leq 2.5 x institutional upper limit of normal unless liver metastases are present, in which case it must be \leq 5x ULN
- Serum creatinine CL > 40 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance:

Males:

$$\text{Creatinine CL} = \frac{\text{Weight (kg)} \times (140 - \text{Age})}{72 \times \text{serum creatinine (mg/dL)}}$$

Females:

$$\text{Creatinine CL} = \frac{\text{Weight (kg)} \times (140 - \text{Age}) \times 0.85}{72 \times \text{serum creatinine (mg/dL)}}$$

6. Female subjects must either be of non-reproductive potential (ie, post-menopausal by history: \geq 60 years old and no menses for \geq 1 year without an alternative medical cause; OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of bilateral oophorectomy) or must have a negative serum pregnancy test upon study entry.
7. Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.
8. Subjects with histologically or cytologically-documented advanced/metastatic lung cancer, head and neck cancer, cervical cancer, melanoma, anal cancer, pancreatic cancer, gastroesophageal cancer, triple negative breast cancer, bladder cancer, renal cancer, Cholangiocarcinoma, Kaposi sarcoma, lymphomas, ovarian cancer, Merkel cell carcinoma or any other tumor type in which anti PD-1 or anti PD-L1 antibodies have demonstrated antitumoral activity, refractory to standard treatment, intolerant of standard treatment, or for which no standard therapy exists or who refuse the standard treatment.

9. Subjects may be included irrespectively of number of previous lines of treatment for advanced disease.
10. Prior palliative radiotherapy must have been completed at least 2 weeks prior to start the study treatment (subjects may receive localized palliative radiotherapy while receiving study drug).
11. Documented HIV-1 infection
12. Undetectable viral load in the last analysis.
13. Subjects with brain metastases are eligible if they are asymptomatic, are treated or are neurological stable for at least 2 weeks without the use of steroids or on stable or decreasing dose of < 10 mg daily prednisone or equivalent.
14. Subjects must be following an antiretroviral therapy at the moment of the inclusion.

4.2 Exclusion criteria

Subjects should not enter the study if any of the following exclusion criteria are fulfilled:

1. Involvement in the planning and/or conduct of the study. Previous enrollment in the present study.
2. Participation in another clinical study with an investigational product during the last 4 weeks.
3. Other untreated coexisting HIV related malignancies.
4. Any previous treatment with a PD1, PD-L1 or PD-L2 inhibitor, including durvalumab.
5. Receipt of the last dose of anti-cancer therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies, other investigational agent) 28 days prior to the first dose of study drug.
6. Mean QT interval corrected for heart rate (QTc) ≥ 470 ms calculated from 3 electrocardiograms (ECGs) using Fridericia's Correction.

7. Current or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid.
8. Any unresolved toxicity (CTCAE grade 2) from previous anti-cancer therapy. Subjects with irreversible toxicity that is not reasonably expected to be exacerbated by the investigational product may be included (e.g., hearing loss, peripherally neuropathy).
9. Any prior Grade ≥ 3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE >Grade 1.
10. Active or prior documented autoimmune disease within the past 2 years
NOTE: Subjects with vitiligo, Grave's disease, or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded.
11. Any syndrome that requires systemic corticosteroid/immunosuppressive medications EXCEPT for syndromes which would not be expected to recur in the absence of an external trigger (vitiligo, autoimmune thyroiditis, or type 1 diabetes mellitus are permitted to enroll).
12. Active or prior documented inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis).
13. History of primary immunodeficiency.
14. History of allogeneic organ transplant.
15. History of hypersensitivity to durvalumab or any excipient.
16. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active bleeding diatheses including any subject known to have evidence of acute or chronic hepatitis B or C, or psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent.
17. Known history of active tuberculosis.

18. Any serious or uncontrolled medical disorder or active infection non HIV, that would impair the ability of the subject to receive the treatment of protocol therapy under treating physician criteria.
19. Subjects with previous malignances (except non melanoma skin cancer, and cancer in situ of: bladder, gastric, colon, cervical/dysplasia, melanoma, breast) are excluded unless a complete remission was achieved at least 5 years prior to study entry and no additional therapy is required or anticipated to be required during the study period.
20. Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab.
21. Female subjects who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control.
22. Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results.
23. Symptomatic or uncontrolled brain metastases requiring concurrent treatment, inclusive of but not limited to surgery, radiation and/or corticosteroids.
24. Subjects with uncontrolled seizures.
25. Patients with tumoral disease in the head and neck region, such as peritracheal or periesophageal lymph node involvement, with infiltration of structures of the digestive, aerea or vascular pathways that represent a risk of increased bleeding.
26. Patients with neuroendocrine tumors of pulmonary origin or pulmonary metastases with evidence of active bleeding.
27. Patients with digestive bleeding.

4.3 Withdrawal of Subjects from Study Treatment and/or Study

Permanent discontinuation of investigational product

An individual subject will not receive any further investigational product if any of the following occur in the subject in question:

1. Withdrawal of consent or lost to follow-up.

2. Adverse event that, in the opinion of the investigator or the sponsor, contraindicates further dosing.
3. Subject is determined to have met one or more of the exclusion criteria for study participation at study entry and continuing investigational therapy might constitute a safety risk.
4. Pregnancy or intent to become pregnant.
5. Any AE that meets criteria for discontinuation as defined in Appendix 1, Section 10.1.3
6. Adverse event related to durvalumab of any Grade>3 ADRs or repetitive Grade 3 ADRs with the exception of toxicities that do not meet the criteria for discontinuation as defined in Section 10.1.3, Appendix 1
7. Grade ≥ 3 infusion reaction.
8. Subject non-compliance that, in the opinion of the investigator or sponsor, warrants withdrawal; eg, refusal to adhere to scheduled visits.
9. Initiation of alternative anticancer therapy including another investigational agent.
10. Confirmation of PD and investigator determination that the subject is no longer benefiting from treatment with durvalumab.

Subjects who are permanently discontinued from further receipt of investigational product, regardless of the reason (withdrawal of consent, due to an AE, other), will be identified as having permanently discontinued treatment.

Subjects who are permanently discontinued from receiving investigational product will be followed for [REDACTED]

[REDACTED], unless consent is withdrawn or the subject is lost to follow-up or enrolled in another clinical study. All subjects will be followed for survival. Subjects who decline to return to the site for evaluations will be offered follow-up by phone every 3 months as an alternative.

Withdrawal of consent

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04

Version Number 4.1

Date 14th November 2018

If consent is withdrawn, the subject will not receive any further investigational product or further study observation.

4.4 Replacement of subjects

Subjects withdrawn from the study will not be replaced.

5. INVESTIGATIONAL PRODUCT(S)

5.1 Durvalumab

The sponsor will supply durvalumab to the site's pharmacies as a 500-mg vial solution for infusion after dilution.

5.1.1 Formulation/packaging/storage

Durvalumab will be supplied by AstraZeneca as a 500-mg vial solution for infusion after dilution. The solution contains 50 mg/mL durvalumab, 26 mM histidine/histidine-hydrochloride, 275 mM trehalose dihydrate, and 0.02% (weight/volume) polysorbate 80; it has a pH of 6.0. The nominal fill volume is 10 mL. Investigational product vials are stored at 2°C to 8°C (36°F to 46°F) and must not be frozen. Durvalumab must be used within the individually assigned expiry date on the label.

The trial medication and its packaging will be labeled in accordance with annex 13 of EU Guidelines to Good Manufacturing Practice.

Term	Percentage
GMOs	~55%
Organic	~95%
Natural	~95%
Artificial	~35%
Organic	~95%
Natural	~95%
Artificial	~35%
Organic	~95%
Natural	~95%
Artificial	~35%

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04

Version Number 4.1

Date 14th November 2018

[REDACTED]

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04 [REDACTED]

Version Number 4.1

Date 14th November 2018

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]

[REDACTED]

5.1.5 Accountability and dispensation

The investigator is responsible for ensuring accountability for trial drug, including reconciliation of drugs and maintenance of drug records.

[REDACTED]

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04

Version Number 4.1

Date 14th November 2018

A horizontal bar chart illustrating the percentage of respondents who have heard of various topics. The y-axis lists the topics, and the x-axis represents the percentage, ranging from 0% to 100% in increments of 10%. The bars are black and set against a white background.

Topic	Percentage
Healthcare	98%
Technology	95%
Finance	92%
Politics	88%
Entertainment	85%
Science	82%
Food	78%
Sports	75%
Business	72%
Art	68%
History	65%
Geography	62%
Mathematics	58%
Chemistry	55%
Physics	52%
Biology	48%
Spanish	45%
French	42%
German	38%
Japanese	35%
Korean	32%
Chinese	28%
Arabic	25%
Russian	22%
Swahili	18%
Portuguese	15%
Urdu	12%
Hindi	10%
Malay	8%
Turkish	5%
Polish	3%
Swedish	2%
French Canadian	1%
Other	1%

6. TREATMENT PLAN

6.1 Subject enrollment

Only persons meeting all inclusion criteria and no exclusion criteria may be enrolled into the trial as subjects. Prior to performing any trial assessments not part of the subject's routine medical care, the investigator will ensure that the subject or his/her legal representative, has provided written informed consent following the procedure.

6.1.1 Procedures for handling subjects incorrectly enrolled

Subjects who are incorrectly enrolled or initiated on treatment should be withdrawn from the study.

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04

Version Number 4.1

Date 14th November 2018

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04

Version Number 4.1

Date 14th November 2018

7. RESTRICTIONS DURING THE STUDY AND CONCOMITANT TREATMENT(S)

7.1 Restrictions during the study

Contraception

Females of childbearing potential who are sexually active with a non sterilised male partner must use effective contraception from screening, and must agree to continue using such precautions for at least 90 days following the last infusion of durvalumab; cessation of birth control after this point should be discussed with a responsible physician. Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control.

- Females of childbearing potential are defined as those who are not surgically sterile (i.e., bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy) or postmenopausal (defined as 12 months with no menses without an alternative medical cause).
- Subjects must use acceptable methods of effective contraception as described in Table 2.
- Non-sterilised males who are sexually active with a female partner of childbearing potential must use acceptable methods of effective contraception (see Table 2) from Day 1 and for 90 days after receipt of the final dose of investigational product.

Table 2. Effective methods of contraception

Barrier Methods	Intrauterine Device Methods	Hormonal Methods
Male condom plus spermicide	Copper T	Implants
Cap plus spermicide	Progesterone T ^a	Hormone shot or injection
Diaphragm plus spermicide	Levonorgestrel-releasing intrauterine system (e.g., Mirena [®]) ^a	Combined pill Minipill Patch

^a This is also considered a hormonal method.

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04

Version Number 4.1

Date 14th November 2018

Blood donation

As patients are HIV infected, they do not donate blood while participating in this study neither after its finalization.

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04

Version Number 4.1

Date 14th November 2018



[Redacted]	[Redacted]

8. STUDY PROCEDURES



Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04 [REDACTED]

Version Number 4.1

Date 14th November 2018

[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04

Version Number 4.1

Date 14th November 2018

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04

Version Number 4.1

Date 14th November 2018

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04

Version Number 4.1

Date 14th November 2018

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04

Version Number 4.1

Date 14th November 2018

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04

Version Number 4.1

Date 14th November 2018

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04

Version Number 4.1

Date 14th November 2018

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04 [REDACTED]

Version Number 4.1

Date 14th November 2018

[REDACTED]

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04

Version Number 4.1

Date 14th November 2018

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04

Version Number 4.1

Date 14th November 2018

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04

Version Number 4.1

Date 14th November 2018

The figure consists of 10 distinct groups of horizontal bars, arranged vertically. Each group contains 3 bars of increasing length from left to right. The bars are solid black and set against a white background. The groups are separated by small gaps.

Group	Bar 1	Bar 2	Bar 3
1	Short	Medium	Long
2	Medium	Long	Very Long
3	Medium	Very Long	Extremely Long
4	Very Long	Extremely Long	Max Length
5	Extremely Long	Max Length	Max Length
6	Extremely Long	Max Length	Max Length
7	Extremely Long	Max Length	Max Length
8	Extremely Long	Max Length	Max Length
9	Extremely Long	Max Length	Max Length
10	Extremely Long	Max Length	Max Length

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04

Version Number 4.1

Date 14th November 2018

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04

Version Number 4.1

Date 14th November 2018

A series of horizontal black bars of varying lengths, likely representing a redacted list of names or identifiers.

10. ASSESSMENT OF SAFETY

The Principal Investigator is responsible for ensuring that all staff involved in the study is familiar with the content of this section.

10.1.1 Safety Parameters

10.1.1.1 Definition of adverse events

The International Conference on Harmonization (ICH) Guideline for Good Clinical Practice (GCP) E6(R1) defines an AE as:

Any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

An AE includes but is not limited to any clinically significant worsening of a subject's pre-existing condition. An abnormal laboratory finding (including ECG finding) that requires an action or intervention by the investigator, or a finding judged by the investigator to represent a change beyond the range of normal physiologic fluctuation, should be reported as an AE.

Adverse events may be treatment emergent (ie, occurring after initial receipt of investigational product) or non treatment emergent. A non treatment-emergent AE is any new sign or symptom,

disease, or other untoward medical event that begins after written informed consent has been obtained but before the subject has received investigational product.

Elective treatment or surgery or preplanned treatment or surgery (that was scheduled prior to the subject being enrolled into the study) for a documented pre-existing condition, that did not worsen from baseline, is not considered an AE (serious or non serious). An untoward medical event occurring during the prescheduled elective procedure or routinely scheduled treatment should be recorded as an AE or SAE.

The term AE is used to include both serious and non-serious AEs.

10.1.2 Definition of serious adverse events

A serious adverse event is an AE occurring during any study phase (i.e., screening, run-in, treatment, wash-out, follow-up), at any dose of the study drugs that fulfils one or more of the following criteria:

- Results in death
- Is immediately life-threatening
- Requires in-patient hospitalization or prolongation of existing hospitalization
- Results in persistent or significant disability or incapacity
- Is a congenital abnormality or birth defect in offspring of the subject
- Is an important medical event that may jeopardize the patient or may require medical intervention to prevent one of the outcomes listed above.
 - Medical or scientific judgment should be exercised in deciding whether expedited reporting is appropriate in this situation. Examples of medically important events are intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias, or convulsions that do not result in hospitalizations; or development of drug dependency or drug abuse.

The causality of SAEs (their relationship to all study treatment/procedures) will be assessed by the investigator(s) and communicated to AstraZeneca.

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04

Version Number 4.1

Date 14th November 2018

[REDACTED]

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04

Version Number 4.1

Date 14th November 2018

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04 [REDACTED]

Version Number 4.1

Date 14th November 2018

[REDACTED]

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04

Version Number 4.1

Date 14th November 2018

10.2 Assessment of safety parameters

10.2.1 Assessment of severity

Assessment of severity is one of the responsibilities of the investigator in the evaluation of AEs and SAEs. Severity will be graded according to the NCI CTCAE v4.03.

The determination of severity for all other events not listed in the CTCAE should be made by the investigator based upon medical judgment and the severity categories of Grade 1 to 5 as defined below:

Grade 1 (mild)	An event that is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living.
Grade 2 (moderate)	An event that is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the subject.
Grade 3 (severe)	An event that requires intensive therapeutic intervention. The event interrupts usual activities of daily living, or significantly affects the clinical status of the subject.
Grade 4 (life threatening)	An event, and/or its immediate sequelae, that is associated with an imminent risk of death or with physical or mental disabilities that affect or limit the ability of the subject to perform activities of daily living (eating, ambulation, toileting, etc).
Grade 5 (fatal)	Death (loss of life) as a result of an event.

It is important to distinguish between serious criteria and severity of an AE. Severity is a measure of intensity whereas seriousness is defined by the criteria in Section 10.1.2. A Grade 3 AE need not necessarily be considered an SAE. For example, a Grade 3 headache that persists for several hours may not meet the regulatory definition of an SAE and would be considered a non-serious event, whereas a Grade 2 seizure resulting in a hospital admission would be considered an SAE.

10.2.2 Assessment of relationship

Investigators must systematically assess the causal relationship of AEs to the trial treatment using the following definitions. Decisive factors for the assessment of causal relationship of an AE to trial treatment include, but may not be limited to, temporal relationship between the AE and treatment administration, known side effects of trial treatment, medical history, concomitant medication, course of the underlying disease, trial procedures.

Not related: Not reasonably related to the trial. The AE could not medically (pharmacologically / clinically) be attributed to the trial treatment in this clinical trial protocol. A reasonable alternative explanation must be available.

Related: Reasonably related to the trial treatment. The AE could medically (pharmacologically / clinically) be attributed to the trial treatment.

TEAEs defined as possibly related to trial treatment will be summarized by Preferred Term and System Organ Class, and described in terms of intensity and relationship to treatment. Treatment emergent AEs are those events with onset dates occurring during the on-treatment period or if the worsening of an event is during the on-treatment period. Any AEs with an onset or worsening date after the on-treatment period will be reported separately.

All premature terminations will be summarized by primary reason for treatment discontinuation/withdrawal.

10.3 Recording of adverse events and serious adverse events

Adverse events will be recorded in the eCRF using a recognized medical term or diagnosis that accurately reflects the event. Adverse events will be assessed by the investigator for severity, relationship to the investigational product, possible etiologies, and whether the event meets criteria of an SAE and therefore requires immediate notification to AstraZeneca/MedImmune Patient Safety.

In cases of surgical or diagnostic procedures, the condition / illness leading to such a procedure is considered as the AE rather than the procedure itself.

According to the Sponsor's convention, any clinical AE with severity of Grade 4 or 5 must also be reported as an SAE; however, a laboratory abnormality of Grade 4, such as anemia or

neutropenia, is considered serious only if the condition meets one of the serious criteria described below. If death occurs, the primary cause of death (or event leading to death) should be recorded and reported as an SAE. “Fatal” will be recorded as the outcome of this respective event; death will not be recorded as a separate event. Only if no cause of death can be reported (for example, sudden death, unexplained death), the death per se might be reported as an SAE.

The following variables will be collected for each AE:

- AE (verbatim)
- The date when the AE started and stopped
- Changes in NCI CTCAE grade and the maximum CTC grade attained
- Whether the AE is serious or not
- Investigator causality rating against durvalumab (yes or no)
- Action taken with regard to durvalumab
- Outcome

In addition, the following variables will be collected for SAEs as applicable:

- Date AE met criteria for serious AE
- Date Investigator became aware of serious AE
- AE is serious due to<<criteria>>
- Date of hospitalization
- Date of discharge
- Probable cause of death
- Date of death
- Autopsy performed
- Description of AE
- Causality assessment in relation to Study procedure(s)

Events, which are unequivocally due to disease progression, should not be reported as an AE during the study.

10.3.1 Study recording period and follow-up for adverse events and serious adverse events

Adverse events and serious adverse events will be recorded from time of signature of informed consent, throughout the treatment period and including the follow-up period (90 days after the last dose of durvalumab).

During the course of the study all AEs and SAEs should be proactively followed up for each subject. Every effort should be made to obtain a resolution for all events, even if the events continue after discontinuation/study completion.

If a subject discontinues from treatment for reasons other than disease progression, and therefore continues to have tumor assessments, drug or procedure-related SAEs must be captured until the patient is considered to have confirmed PD and will have no further tumor assessments.

The investigator is responsible for following all SAEs until resolution, until the subject returns to baseline status, or until the condition has stabilized with the expectation that it will remain chronic, even if this extends beyond study participation.

Follow-up of unresolved adverse events

Any AEs that are unresolved at the subject's last visit in the study are followed up by the investigator for as long as medically indicated, but without further recording in the eCRF. After 90 days, only subjects with ongoing investigational product-related SAEs will continue to be followed for safety.

AstraZeneca/MedImmune retains the right to request additional information for any subject with ongoing AE(s)/SAE(s) at the end of the study, if judged necessary.

Post study events

After the subject has been permanently withdrawn from the study, there is no obligation for the investigator to actively report information on new AE or SAEs occurring in former study subjects after the 90-day safety follow-up period for patients treated with durvalumab. However, if an investigator learns of any SAEs, including death, at any time after the subject has been permanently withdrawn from study, and he/she considers there is a reasonable possibility that the event is related to study treatment, the investigator should notify the study sponsor and AstraZeneca/MedImmune Drug Safety.

10.3.2 Reporting of serious adverse events

All SAEs will be reported, whether or not considered causally related to the investigational product, or to the study procedure(s). The Sponsor is responsible for informing the Regulatory Authorities of the SAE as per local requirements.

The sponsor must inform local Health Authorities, via a CIOMS form, of any serious or unexpected adverse events that occur, and will concurrently forward all such reports to AstraZeneca. A copy of the CIOMS report must be faxed to AstraZeneca at the time the event is reported to local Health Authorities. It is the responsibility of the sponsor to compile all necessary information and ensure that the local Health Authorities receives a report according to the local reporting requirement timelines and to ensure that these reports are also submitted to AstraZeneca at the same time.

* A *cover page* should accompany the CIOMS form indicating the following:

- “Notification from an Investigator Sponsored Study”
- The EudraCT Number
- The sponsor’s name and address
- The trial name/title and ESR reference number (ESR-##-#####)

* Sponsor must also indicate, either in the SAE report or the cover page, the *causality* of events *in relation to all study medications* and if the SAE is *related to disease progression*, as determined by the principal investigator.

* [REDACTED]

If a non-serious AE becomes serious, this and other relevant follow-up information must also be provided to AstraZeneca and the local Health Authorities.

Serious adverse events that do not require expedited reporting to local Health Authorities still need to be reported to AstraZeneca preferably using the MedDRA coding language for serious adverse events. This information should be reported on a monthly basis and under no circumstance less frequently than quarterly.

10.3.3 Reporting of deaths

All deaths that occur during the study, or within the protocol-defined 90-day post-last dose of durvalumab safety follow-up period must be reported as follows:

- Death that is clearly the result of disease progression should be documented but should not be reported as an SAE.

- Where death is not due (or not clearly due) to progression of the disease under study, the AE causing the death must be reported to as a SAE within **24 hours** (see Section 10.3.2 for further details). The report should contain a comment regarding the co-involvement of progression of disease, if appropriate, and should assign main and contributory causes of death.
- Deaths with an unknown cause should always be reported as a SAE.

Deaths that occur following the protocol-defined 90-day post-last-dose of durvalumab safety follow-up period will be documented as events for survival analysis, but will not be reported as an SAE.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

10.3.7 Pregnancy

10.3.8 Maternal exposure

If a patient becomes pregnant during the course of the study, the IPs should be discontinued immediately.

Pregnancy itself is not regarded as an AE unless there is a suspicion that the IP under study may have interfered with the effectiveness of a contraceptive medication. Congenital abnormalities or birth defects and spontaneous miscarriages should be reported and handled as SAEs. Elective abortions without complications should not be handled as AEs. The outcome of all pregnancies (spontaneous miscarriage, elective termination, ectopic pregnancy, normal birth, or congenital abnormality) should be followed up and documented even if the patient was discontinued from the study.

If any pregnancy occurs in the course of the study, then the Investigator or other site personnel should inform the appropriate AstraZeneca representatives within 1 day, ie, immediately, but **no later than 24 hours** of when he or she becomes aware of it.

The same timelines apply when outcome information is available.

10.3.9 Paternal exposure

Male patients should refrain from fathering a child or donating sperm during the study and for 90 days after the last dose of durvalumab monotherapy.

Pregnancy of the patient's partner is not considered to be an AE. However, the outcome of all pregnancies (spontaneous miscarriage, elective termination, ectopic pregnancy, normal birth, or congenital abnormality) occurring from the date of the first dose until 90 days after the last dose should, if possible, be followed up and documented.

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04 [REDACTED]

Version Number 4.1

Date 14th November 2018

Where a report of pregnancy is received, prior to obtaining information about the pregnancy, the Investigator must obtain the consent of the patient's partner. Therefore, the local study team should adopt the generic ICF template in line with local procedures and submit it to the Ethics Committees (ECs) prior to use.

11. STATISTICAL METHODS AND SAMPLE SIZE DETERMINATION

11.1 Description of analysis sets

The screening analysis set includes all subjects who signed the ICF.

ITT Analysis set: the ITT analysis set will include all subjects who were included into the trials.

Per-protocol analysis set will include all ITT subjects who do not have major protocol violations.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

11.2 Methods of statistical analyses

In general descriptive summaries will be presented for the efficacy and safety variables collected. Continuous variables will be summarized using mean, standard deviation, minimum, median, and maximum. Categorical variables will be summarized using frequency counts and percentages.

Unless otherwise specified, the calculation of proportions will be based on the sample size of the population of interest. Count missing observations will be included in the denominator and presented in a separate category.

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04

Version Number 4.1

Date 14th November 2018

[REDACTED]

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04

Version Number 4.1

Date 14th November 2018

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04 [REDACTED]

Version Number 4.1

Date 14th November 2018

[REDACTED]

[REDACTED]

[REDACTED]

12. ETHICAL AND REGULATORY REQUIREMENTS

12.1 Ethical conduct of the study

The study will be performed in accordance with ethical principles that have their origin in the Declaration of Helsinki and are consistent with ICH/Good Clinical Practice, and applicable regulatory requirements Subject data protection.

12.2 Ethics and regulatory review

The Investigator is responsible for the conduct of the trial at his site. He/she will ensure that the trial is performed in accordance with the clinical trial protocol and with the ethical principles that have their own origin in the Declaration of Helsinki, as well as with the ICH Note for Guidance on GCP (ICH Topic E6, 1996) and applicable regulatory requirements. In particular the investigator must ensure that only patients who have their informed consent are included in the trial.

12.3 Informed consent

An unconditional prerequisite for a subject's participation in the trial is his/her written informed consent. The subject's written consent to participate in the trial must be given before any trial-related activities are carried out. [REDACTED]

[REDACTED]

[REDACTED]

Adequate information must therefore be given to the subject by the Investigator before informed consent is obtained (a person designated by the Investigator may give the information, if permitted by local regulations). A subject information sheet in the local language and prepared in accordance with the Note for Guidance on GCP (ICH Topic E6, 1996) will be provided by the Sponsor for the purpose of obtaining informed consent. In addition to providing this written information to a potential subject, the Investigator or his /her designate will inform the subject

verbally of all aspects of the trial. The language used in doing so must be chosen so that the information can be fully and readily understood by lay persons.

The ICF must be signed and personally dated by the Investigator and the subject.

The signed and dated declaration of informed consent will remain at the Investigator's site, and must be safely archived. A copy of the signed and dated information and ICF should be provided to the subject prior to participation.

Data protection and privacy regulations will be observed in capturing, forwarding, processing, and storing subject data. Subjects will be informed accordingly and will be requested to give their consent on data handling procedures in accordance with national regulations.

A unique subject number will be assigned to each subject at inclusion by IVRS system, immediately after informed consent has been obtained. This number will serve as the subject's identifier in the trial as well as in the clinical trial database. The subject's data will be stored under this number. Only the investigator will be able to link the subject's identity with the subject trial data via an identification list kept at the site. The medical data that are reviewed at the site during the source data verification by the Clinical Trial Monitor, audits, and Health Authority inspections will be kept strictly confidential.

Subjects will be informed accordingly and will be requested to give their consent on data handling procedures in accordance with national regulations.

12.4 Changes to the protocol and informed consent form

Any change in the approved protocol will require a Protocol amendment. The Investigator must not make any change in the study without favorable opinion from the Ethics Committee and authorization from the Health Authorities, except as necessary to eliminate an impending and obvious risk for the subjects except when necessary to remove an apparent, immediate hazard to subjects. Protocol changes introduced to eliminate an impending and obvious risk may be implemented immediately, but must subsequently be documented in an amendment, reported to the Ethics Committee and be submitted to the relevant Health Authorities within the required timeframe.

Any substantial amendments to the protocol must be submitted in writing to the Investigator's Ethics Committee and the Health Authorities for approval before the changes proposed in the

amendment are implemented. Depending on the magnitude of the change, the recruitment may be temporally halted.

The sponsor does not have to notify non-substantial amendments to the Health Authorities or the Ethics Committee. However, any non-substantial amendments will be recorded and contained in the documentation when it is subsequently submitted, for example in the subsequent notification of a substantial amendment. Documentation of any non-substantial amendments will be available on request for inspection at the trial site or the sponsor premises as appropriate.

Whenever important new information becomes available that may be relevant to the subject's consent, the written subject information sheet and any other written information provided to subjects will be revised by the Sponsor or designee and be submitted again to the IEC/IRB for review and favorable opinion. The agreed, revised information will be provided to each subject in the trial for signing and dating. The Investigator will explain the changes to the previous version.

12.5 Audits and inspections

This trial will be monitored in accordance with the ICH Note for Guidance on GCP (ICH Topic E6, 1996). The clinical Trial Monitor will perform visits to the trial site at regular intervals.

Representatives of the Sponsor's Quality Assurance unit or a designated organization, as well as Health Authorities, must be permitted to inspect all trial-related documents and other materials at the site, including the Investigator Site File, the completed eCRFs, the trial drug, and the subject's original medical records/files.

The clinical trial protocol, each step of the data capture procedure, and the handling of the data, including the final clinical trial report, will be subject to independent quality assurance activities. Audits may be conducted at any time during or after the trial to ensure the validity and integrity of the trial data.

12.6 Insurance

The sponsor contracts an insurance policy to cover the responsibilities of the investigator and other parties participating in the study, according to the applicable Spanish legislation.

[REDACTED]

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04 [REDACTED]

Version Number 4.1

Date 14th November 2018

12.7 Publications

The sponsor commits to responsible publication of both the positive and negative results from its clinical trials as required by all governing regulatory and health authorities.

Investigators will not publish the global study results (all sites) unless the sponsor has not done so in a suitable time period after the clinical study report (CSR) has been available. Should the Investigator(s) independently seek to publish results of this study which occur at their study site(s), they must inform the study sponsor of any/all drafts (including, but not limited to papers, manuscripts or abstracts) at least 60 days before submission to the congress, meeting or journal.

The sponsor and Investigator(s) will agree with all aspects related to any proposed publications with regards to the following: 1) any proposed publications will be drafted in agreement with international recommendations, such as those from the International Committee of Medical Journal Editors (ICMJE) and all elements of the Consort Statement (2010), to maintain integrity of the trial results in all communications; 2) any proposed publications will state the Clinical Research Ethics Committees which approved the trial and the funding sources of the trial; 3) any proposed publications will occur before disclosure of results to lay people; 4) any proposed publications will not report premature or partial data prior to completion of the analysis of the overall results of the trial.

13. STUDY MANAGEMENT

13.1 Training of study site personnel

The principal investigator will maintain a record of all center staff involved in the clinical trial (doctors, nurses and other staff involved) ensuring that they receive appropriate training to perform the study, and that any new information of relevance to the study will be transmitted to them.

Researchers will be instructed about the procedures of the trial in the investigator meeting and/or initiation visits made by monitors at each participating center prior to the study start.

13.2 Monitoring of the study

Spanish Lung Cancer Group is the company responsible for monitoring the study (see appendix 5). The clinical monitors have the obligation to follow the trial closely so that all aspects of the trial are carefully monitored for compliance with applicable government regulations and with ICH E6 (R1) guidelines.

The clinical monitors will visit the study sites and Investigators at intervals as defined in the monitoring plan, in addition to maintaining necessary contact through telephone, e-mail, and letter. The clinical monitors will maintain current personal knowledge of the trial through observation, review of trial records and source documentation, and discussion of the conduct of the trial with the study site Investigators and staff.

13.2.1 Source data

Source documents are all documents used by the Investigator or hospital that relate to the subject's medical history, that verify the existence of the subject, the inclusion and exclusion criteria, and all records covering the subject's participation in the study. They include enrolment log, investigational product accountability log, laboratory notes, memoranda, material dispensing records, subject files, etc. The eCRF is essentially considered a data entry form and should not constitute the original (or source) medical records unless otherwise specified.

Each Investigator is responsible for maintaining source documents. These will be made available for inspection by the study monitor at each monitoring visit. All supportive documentation submitted with the eCRF, such as laboratory data should be clearly identified with the study, visit and subject number. Any personal information (e.g., subject name, initials) should be removed or rendered illegible to preserve individual confidentiality.

13.2.2 Study documentation

The Investigator will be provided with an Investigator Site File upon initiation of the trial. This file will contain all documents necessary for the conduct of the trial and will be updated and completed throughout the trial. It must be available for review by the Monitor, and must be ready for Sponsor audit as well as for inspection by Health Authorities during and after the trial, and must be safely archived for at least 25 years after the end of the trial. The documents to be archived include the Subject Identification List and the signed subject ICFs. If archiving of the Investigator Site File is no longer possible at the site, the Investigator must notify the Sponsor. All original subject files (medical records) must be stored at the site (hospital, research institute, or practice) for the longest possible time permitted by the applicable regulations, and / or as per ICH GCP guidelines, whichever is longer. In any case, the Investigator should ensure that no destruction of medical records is performed without the written approval of the Sponsor.

13.3 Study timetable and end of study

End of study is defined as Last Subject Last Visit.

- Recruitment period will be 12 months

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

14. DATA MANAGEMENT

The Investigator or designee will be responsible for entering trial data in the eCRF provided by the CRO and follow the data entry guidelines. It is the Investigator's responsibility to ensure the accuracy of the data entered in the eCRFs and to sign the case report forms.

The data will be entered into a validated database. The CRO will be responsible for data review and processing, in accordance with the CRO's data management procedures.

The principal CRO functions in data management are CRF tracking and query generation, tracking and resolution as well as to perform Eligibility, Treatment, AE, Response checks and inform Medical Reviewers if any doubt regarding eligibility comes up.

Data Manager (DM) will check the database twice a week or when necessary, depending on the recruitment of the Study.

Queries issued by the DM will show up in the eCRF.

DM will send an e-mail to the investigators according the quantity of queries to be solved requesting their resolution as soon as possible. If there would be a lot of queries at the same center, DM will send an e-mail/reminder once a week.

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04 [REDACTED]

Version Number 4.1

Date 14th November 2018

DM have to access to the eCRF in regular intervals to check if any queries have been solved. The participant centers have to access to the eCRF to check if any queries have been issued in their patients.

The data review will be done from the first patient included until the last follow of the last patient reported in the eCRF.

The data cleaning consists of the exhaustive review of data from the baseline to the end of the follow up of the patient, performing queries when necessary.

DM reviewers will follow the most current version of the Fundación GECP's Data Management SOP.

The field which have to be reviewed by DM will be detailed in the eCRF Data Management Manual.

Database lock will occur once quality control procedures and quality assurance procedures (if applicable) have been completed.

Copies of the eCRFs will be provided to the Investigators at the completion of the trial.

The Investigator must keep a subject file (medical file, original medical records) on paper or electronically for every subject included in the trial. This file will contain the available demographic and allmedical information for the subject, and should be as complete as possible.

14.1 Study governance and oversight

The safety of all AstraZeneca products is closely monitored on an ongoing basis by AstraZeneca representatives in consultation with Patient Safety. Issues identified will be addressed; for instance, this could involve amendments to the study protocol and letters to Investigators.

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04 [REDACTED]

Version Number 4.1

Date 14th November 2018

15. LIST OF REFERENCES

[REDACTED]

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04 [REDACTED]

Version Number 4.1

Date 14th November 2018

[REDACTED]

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04

Version Number 4.1

Date 14th November 2018

Clinical Study Protocol


Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04 [REDACTED]









Version Number 4.1

Date 14th November 2018

Appendix 1







Clinical Study Protocol


Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04 [REDACTED]

Version Number 4.1

Date 14th November 2018

Appendix 1





Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04 [REDACTED]

Version Number 4.1

Date 14th November 2018

[REDACTED] m i mediated [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04 [REDACTED]

Version Number 4.1

Date 14th November 2018

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04 [REDACTED]

Version Number 4.1

Date 14th November 2018

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04 [REDACTED]

Version Number 4.1

Date 14th November 2018

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04 [REDACTED]

Version Number 4.1

Date 14th November 2018

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04 [REDACTED]

Version Number 4.1

Date 14th November 2018

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04

Version Number 4.1

Date 14th November 2018

A 2D bar chart with a light blue background. The y-axis has 10 horizontal bars. The x-axis has 10 vertical bars. The bars are black, with varying heights and widths. A vertical line is drawn at x=10. A horizontal line is drawn at y=10. The bars are positioned such that they overlap and form a grid-like pattern.

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04 [REDACTED]

Version Number 4.1

Date 14th November 2018


Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04 [REDACTED]

Version Number 4.1

Date 14th November 2018




Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04 [REDACTED]

Version Number 4.1

Date 14th November 2018




Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04 [REDACTED]

Version Number 4.1

Date 14th November 2018



Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04 [REDACTED]

Version Number 4.1

Date 14th November 2018

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04 [REDACTED]

Version Number 4.1

Date 14th November 2018

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04 [REDACTED]

Version Number 4.1

Date 14th November 2018

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04 [REDACTED]

Version Number 4.1

Date 14th November 2018

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04 [REDACTED]

Version Number 4.1

Date 14th November 2018

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04 [REDACTED]

Version Number 4.1

Date 14th November 2018

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04 [REDACTED]

Version Number 4.1

Date 14th November 2018

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04 [REDACTED]

Version Number 4.1

Date 14th November 2018

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04 [REDACTED]

Version Number 4.1

Date 14th November 2018

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04 [REDACTED]

Version Number 4.1

Date 14th November 2018

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04 [REDACTED]

Version Number 4.1

Date 14th November 2018

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04 [REDACTED]

Version Number 4.1

Date 14th November 2018

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04 [REDACTED]

Version Number 4.1

Date 14th November 2018

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04 [REDACTED]

Version Number 4.1

Date 14th November 2018

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04 [REDACTED]

Version Number 4.1

Date 14th November 2018

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04 [REDACTED]

Version Number 4.1

Date 14th November 2018

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04 [REDACTED]

Version Number 4.1

Date 14th November 2018

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04 [REDACTED]

Version Number 4.1

Date 14th November 2018

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04 [REDACTED]

Version Number 4.1

Date 14th November 2018



Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04 [REDACTED]

Version Number 4.1

Date 14th November 2018

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04 [REDACTED]

Version Number 4.1

Date 14th November 2018

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04

Version Number 4.1

Date 14th November 2018

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04

Version Number 4.1

Date 14th November 2018

This figure is a complex black and white diagram, likely a scan of a document page. It features a grid structure with horizontal and vertical lines. The top portion is dominated by a large black rectangular area. Below this, the grid is defined by a thick black border on the left and a thin black border on the top. The grid area contains numerous horizontal bars of varying lengths and vertical bars of varying heights. Some horizontal bars are grouped together, while others are isolated. Some vertical bars are grouped together, while others are isolated. The overall pattern is a dense, abstract representation of data or a complex system.

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04

Version Number 4.1

Date 14th November 2018

This figure is a horizontal bar chart with 10 rows of data. The first row has a large black bar on the left and a smaller black bar on the right. The second row has a large black bar on the left and a grid of black bars in the middle. The third row has a large black bar on the left and a series of black bars of varying lengths on the right. The fourth row has a large black bar on the left and a series of black bars of varying lengths on the right. The fifth row has a large black bar on the left and a series of black bars of varying lengths on the right. The sixth row has a large black bar on the left and a series of black bars of varying lengths on the right. The seventh row has a large black bar on the left and a series of black bars of varying lengths on the right. The eighth row has a large black bar on the left and a series of black bars of varying lengths on the right. The ninth row has a large black bar on the left and a series of black bars of varying lengths on the right. The tenth row has a large black bar on the left and a series of black bars of varying lengths on the right.

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04

Version Number 4.1

Date 14th November 2018

a

Appendix 5: Contact Details

Pintor Baeza, 11

03010 Alicante

Clinical Study Protocol

Drug Substance Durvalumab (Medi4736)

Sponsor code: GECP 16/04 [REDACTED]

Version Number 4.1

Date 14th November 2018

[REDACTED]
CRO

Fundación GECP
Avenida Meridiana 358, 6^a planta
08027 Barcelona
Phone Number. +34 93 430 20 06
Fax. +34 93 419 17 68
E-mail: secretaria@gecp.org

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]